|
|
||||||||||
|
James C. Lynch, PhD
Student Life Center, 3027 Professional Summary Dr. Lynch joined the Biostatistics Section in 1996 and became Section Chief in 1999. He has served as the Director of the UNMC Eppley Cancer Center Biostatistics Shared Resource since its formation in 2000. He serves as the biostatistical member of both the UNMC Eppley Cancer Center Scientific Review Committee and the Clinical Research Center Scientific Advisory Committee. He was a member of the Intergroup Rhabdomyosarcoma Study Group Statistical Center until its integration into the Children’s Oncology Group in 2000. He remains a member of the COG Statistics and Data Center Omaha office and a member of the Soft Tissue Sarcoma committee. He also serves as the lead statistician for the COG Hematopoietic Stem Cell Transplant and Non-Hodgkin’s Lymphoma committees. Courses Taught
PSM 806, Fall 1998, Fall 2005 Education
Selected Publications Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A. (2000) A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96, 80-5. Joshi SS, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A, and Bishop MR. (2001). Decreased immune functions of blood cells following mobilization with G-CSF: association with donor characteristics. Blood. 98, 1963-70. Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, Bociek G, Enke C, Bast M, Chan WC and Armitage JO for the Nebraska Lymphoma Study Group. (2002). Hodgkin’s disease in the elderly-improved treatment outcome with a doxorubicin-containing regimen. Journal of Clinical Oncology 20, 1087-93. Sorenson PHB, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer H, Crist W, Bridge J, Triche TJ, and Barr FG (2002). PAX3-FKHR and PAX7-FKHR Gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group. Journal of Clinical Oncology, 20: 2672-2679. Bierman, PJ, Lynch JC, Bociek RG, Whalen VL, Kessinger A, Vose JM, and Armitage JO (2002). The International Prognostic Factors Project Score for advanced Hodgkin’s disease is useful for autologous stem cell transplantation. Annals of Oncology 13, 1370-7. Joshi SS, Bishop MR, Lynch JC, Tarantolo SR, Abhyankar S, Bierman PJ, Vose JM, Geller RB, McQuirk J, Foran J, Bociek RG, Hadi A, Day SD, Armitage JO, Kessinger A, and Pavletic SZ. (2003). Immunological and clinical effects of post-transplant G-CSF versus placebo in T-Cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy 5, 542-52. Pavletic SZ, Smith LM, Lynch JC, Bishop MR, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, and Kessinger A. (2005) Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem cell transplantation. American Journal of Hematology 78, 265-274. Ganti AK, Bierman PJ, Lynch JC, Bociek RG, Vose JM, and Armitage JO. (2005) Hematopoietic stem cell transplantation in mantle cell lymphoma. Annals of Oncology 16, 618-624. Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, and Lynch JC. (2005) Low dose chemotherapy for refractory post-transplant lymphoproliferative disease in children following solid organ transplantation. Journal of Clinical Oncology 23, 6481-6488. Professional Affiliations
Children's Oncology Group | ||||||||||
